These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 15194000)
1. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Beretta GL; Gatti L; Tinelli S; Corna E; Colangelo D; Zunino F; Perego P Biochem Pharmacol; 2004 Jul; 68(2):283-91. PubMed ID: 15194000 [TBL] [Abstract][Full Text] [Related]
2. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138 [TBL] [Abstract][Full Text] [Related]
3. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Katano K; Kondo A; Safaei R; Holzer A; Samimi G; Mishima M; Kuo YM; Rochdi M; Howell SB Cancer Res; 2002 Nov; 62(22):6559-65. PubMed ID: 12438251 [TBL] [Abstract][Full Text] [Related]
4. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines. Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364 [TBL] [Abstract][Full Text] [Related]
5. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Shang X; Lin X; Manorek G; Howell SB Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666 [TBL] [Abstract][Full Text] [Related]
6. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. Kalayda GV; Wagner CH; Jaehde U J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323 [TBL] [Abstract][Full Text] [Related]
7. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Samimi G; Howell SB Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571 [TBL] [Abstract][Full Text] [Related]
8. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Safaei R; Howell SB Crit Rev Oncol Hematol; 2005 Jan; 53(1):13-23. PubMed ID: 15607932 [TBL] [Abstract][Full Text] [Related]
9. Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin. Matsumoto S; Tanaka T; Kurokawa H; Matsuno K; Hayashida Y; Takahashi T Anticancer Res; 2007; 27(4B):2209-16. PubMed ID: 17695505 [TBL] [Abstract][Full Text] [Related]
10. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B. Ahmed Z; Deyama Y; Yoshimura Y; Suzuki K Cancer Chemother Pharmacol; 2009 Mar; 63(4):643-50. PubMed ID: 18545997 [TBL] [Abstract][Full Text] [Related]
11. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Holzer AK; Samimi G; Katano K; Naerdemann W; Lin X; Safaei R; Howell SB Mol Pharmacol; 2004 Oct; 66(4):817-23. PubMed ID: 15229296 [TBL] [Abstract][Full Text] [Related]
12. Dual role of LRRC8A-containing transporters on cisplatin resistance in human ovarian cancer cells. Sørensen BH; Dam CS; Stürup S; Lambert IH J Inorg Biochem; 2016 Jul; 160():287-95. PubMed ID: 27112899 [TBL] [Abstract][Full Text] [Related]
13. Cross-resistance to cisplatin in cells with acquired resistance to copper. Safaei R; Katano K; Samimi G; Naerdemann W; Stevenson JL; Rochdi M; Howell SB Cancer Chemother Pharmacol; 2004 Mar; 53(3):239-46. PubMed ID: 14648017 [TBL] [Abstract][Full Text] [Related]
14. Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Buß I; Hamacher A; Sarin N; Kassack MU; Kalayda GV Metallomics; 2018 Mar; 10(3):414-425. PubMed ID: 29417972 [TBL] [Abstract][Full Text] [Related]
15. Uptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306. Fung KL; Tepede AK; Pluchino KM; Pouliot LM; Pixley JN; Hall MD; Gottesman MM Mol Pharm; 2014 Aug; 11(8):2692-702. PubMed ID: 24800945 [TBL] [Abstract][Full Text] [Related]
16. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Samimi G; Katano K; Holzer AK; Safaei R; Howell SB Mol Pharmacol; 2004 Jul; 66(1):25-32. PubMed ID: 15213293 [TBL] [Abstract][Full Text] [Related]
17. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Komatsu M; Sumizawa T; Mutoh M; Chen ZS; Terada K; Furukawa T; Yang XL; Gao H; Miura N; Sugiyama T; Akiyama S Cancer Res; 2000 Mar; 60(5):1312-6. PubMed ID: 10728692 [TBL] [Abstract][Full Text] [Related]
18. Expression profile of copper transporters in sensitive and cisplatin/oxaliplatin-resistant tumor cell lines. Kassack MU; Stratenschulte C Int J Clin Pharmacol Ther; 2005 Dec; 43(12):597-8. PubMed ID: 16372532 [No Abstract] [Full Text] [Related]
19. [Cisplatin induces drug resistance in human esophageal squamous carcinoma cell line EC109 by decreasing CTR1 protein expression]. Yu L; Chen MH; Gu CP; Li YL; Wen J; Fu JH; Cho CH; Liu SW Nan Fang Yi Ke Da Xue Xue Bao; 2011 May; 31(5):801-4. PubMed ID: 21602128 [TBL] [Abstract][Full Text] [Related]
20. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Holzer AK; Manorek GH; Howell SB Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]